Articles related to ASCO

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

A study on palliative care for advanced lung cancer patients shows that telehealth can match in-person visits in improving quality of life and patient satisfaction. These findings support the broader implementation of telehealth in oncology.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

The 2024 ASCO Annual Meeting reveals critical updates on lung and blood cancers, including promising phase 3 trial results and the innovative use of AI to reengage marginalized patients in cancer care.

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.